Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.31 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management did not offer detailed insights into financial performance or future guidance. The emphasis was on continuing their research initiatives.
Management did not provide specific updates on revenue or future expectations.
The focus remains on ongoing research and development efforts.
Kodiak Sciences reported a loss of $0.31 per share, but did not disclose revenue figures. The stock dropped nearly 10% following the earnings release, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's ability to generate revenue and its ongoing research efforts.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DAVE INC A
Aug 12, 2019